Home / Health / Brazil OKs World's First Single-Dose Dengue Vaccine
Brazil OKs World's First Single-Dose Dengue Vaccine
27 Nov
Summary
- Brazil approved the first single-dose dengue vaccine, Butantan-DV.
- The vaccine is 91.6% effective against severe dengue.
- Brazil aims for 30 million doses by late 2026.
In a landmark decision, Brazilian health authorities have authorized the world's first single-dose dengue vaccine, Butantan-DV. This development is hailed as a significant scientific achievement, particularly as dengue cases surge globally due to climate change.
The vaccine, developed over eight years by the Butantan Institute, demonstrated an impressive 91.6% efficacy against severe dengue in clinical trials involving over 16,000 volunteers. Its single-dose nature promises to streamline vaccination efforts, offering a faster and more accessible defense against the debilitating mosquito-borne illness.
Brazil has secured an agreement to produce approximately 30 million doses by the second half of 2026. This vital advancement arrives as dengue, known for its severe flu-like symptoms, reached record global levels in 2024, with researchers linking its spread to warming temperatures.
